Acutaas Chemical Q1 FY27 Earnings Call — Analysis (NSE: ACUTAAS)

Acutaas Chemicals starts FY27 with 59% revenue growth and begins commercial battery chemical supply while maintaining 25% full-year revenue guidance

28 Jul 2026 · Analysis by Alpha Inflection

The take

Q1FY27 Revenue ₹329.7 Cr ( +59.1% YoY ) . New guidance — FY27 fy27 revenue growth and ebitda… 25% . New story: Battery chemicals rapid ramp-up .

Results

Revenue ₹329.7 Cr +59.1% YoY; EBITDA margin 34.3% (+973 bps YoY); PAT ₹74.9 Cr +70.4% YoY

Financial highlights

Guidance

FY27 revenue growth expected at 25% with margins similar to FY26; battery chemicals to ramp to full capacity in 3 years

What management committed to

• The company will deliver 25% revenue growth for FY27 with stable margins (similar to FY26) — 25%, FY27
• The overall Specialty Chemicals segment will not decline in FY27, as growth in BFC and new battery chemical/replacement products will more than offset the decline in commodity chemicals — FY27
• [Battery chemicals plant] will hit full capacity utilisation of 2,000 MT VC and 2,000 MT FEC by end of 3 years — full capacity utilization (4,000 MT), FY29
• CDMO revenue will reach INR1,000 Cr, and the company is confident to beat this target — INR1,000 crores
• Pharma Intermediates revenue share will decline from 87% (FY26) to around 80% in next 3 years — around 80%, FY29
• [Indichem semiconductor plant] will fill full capacity in 3 to 4 years' time — FY30
• Employee cost for FY27 will be around INR150 crores — INR150 crores, FY27
• Phase 2 capex for the third electrolyte additive product will be completed by end of Q2 FY27 — Q2FY27

Key themes

Battery chemicals ramp-up, CDMO expansion, commodity phase-out

How the narrative shifted

• Battery chemicals rapid ramp-up: Management frames battery chemicals as a demand-unconstrained business with long-term supply contracts, expecting rapid revenue scale-up as capacity comes online.
• CDMO pipeline and INR1,000 Cr target: The CDMO business is positioned as the anchor growth engine with a visible pipeline of 30–40 molecules per year and confidence to exceed the INR1,000 Cr revenue target.
• Commodity phase-out and margin-mix shift: Phasing out low-margin commodity chemicals in Specialty Chemicals and replacing them with higher-margin products is expected to improve segment mix without reducing overall segment revenue.
• Semiconductor chemicals (Indichem) as structural AI play: Indichem plant is ahead of schedule; management links demand to structural AI-driven CPU/memory chip growth, positioning photoresist chemicals as a multi-year opportunity.
• Geopolitical raw-material disruption managed: Gulf tensions created a turbulent start, but the team secured raw material availability and maintained supply continuity; no guidance impact.
• Broad-based capex cycle underway: Multiple growth projects (battery, pilot plant, R&D centre, land acquisition) are in planning or execution, signalling a multi-year investment phase to support capacity.

Operational commentary

• Battery chemicals plant successfully completed trial run and started commercial supply; demand unprecedented, rapid ramp-up expected
• Indichem semiconductor plant construction ahead of schedule, capex completion expected by end of Q2FY27, revenue from next financial year
• Electrolyte additive Phase 2 (third product) capex on track to complete by end Q2FY27, signed supply contract in place, trial runs imminent
• Specialty Chemicals portfolio restructuring: phasing out commodity chemicals, replacing with higher-margin products; no overall segment decline expected in FY27
• CDMO business grew strongly YoY; core Pharma Intermediates also robust, driven by top products and new products gaining volume
• R&D pipeline healthy, developing 30–40 molecules annually; management confident of beating the INR1,000 Cr CDMO revenue target
• Capacity utilization: Sachin 83%, Ankleshwar 23%, Jhagadia 55%
• Planned capex for FY27: ~INR50 Cr for electrolyte additives and pilot plant, INR40–45 Cr maintenance capex; additional R&D centre and land acquisition not yet finalised

Analyst Q&A

• Q. Can you quantify the battery chemicals revenue recognised this quarter and the expected FY27 number?

  We have started supply and it will ramp up very fast, but I'm afraid I will not be able to share a particular number.

• Q. Could you split the growth rates between CDMO and the base Advanced Intermediates business within Pharma?

  We are not giving any split between CDMO and non‑CDMO in Pharma Intermediates space; I'm afraid I will not be able to share those numbers.

• Q. What products beyond photoresist chemicals will be manufactured at Indichem?

  There are multiple projects we are working on at Indichem R&D, but I'm afraid I will not be able to share details about those things as of now.

• Q. On a steady‑state basis, what margin profile can we expect for Indichem?

  It is still premature as of now to give any number on this.

View source

Research and educational content only. Not investment advice.